<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24521134</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Recent developments in antiviral agents against enterovirus 71 infection.</ArticleTitle><Pagination><StartPage>14</StartPage><MedlinePgn>14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1423-0127-21-14</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV-71) is the main etiological agent of hand, foot and mouth disease (HFMD). Recent EV-71 outbreaks in Asia-Pacific were not limited to mild HFMD, but were associated with severe neurological complications such as aseptic meningitis and brainstem encephalitis, which may lead to cardiopulmonary failure and death. The absence of licensed therapeutics for clinical use has intensified research into anti-EV-71 development. This review highlights the potential antiviral agents targeting EV-71 attachment, entry, uncoating, translation, polyprotein processing, virus-induced formation of membranous RNA replication complexes, and RNA-dependent RNA polymerase. The strategies for antiviral development include target-based synthetic compounds, anti-rhinovirus and poliovirus libraries screening, and natural compound libraries screening. Growing knowledge of the EV-71 life cycle will lead to successful development of antivirals. The continued effort to develop antiviral agents for treatment is crucial in the absence of a vaccine. The coupling of antivirals with an effective vaccine will accelerate eradication of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Chee Wah</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Jeffrey Kam Fatt</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Sam</LastName><ForeName>I-Ching</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Yoke Fun</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. chanyf@ummc.edu.my.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24521134</ArticleId><ArticleId IdType="pmc">PMC3924904</ArticleId><ArticleId IdType="doi">10.1186/1423-0127-21-14</ArticleId><ArticleId IdType="pii">1423-0127-21-14</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;39:195&#x2013;205. doi: 10.1016/0168-1702(95)00087-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal structure of human enterovirus 71. Science. 2012;336:1274. doi: 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S. et al.Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979;60:329&#x2013;340. doi: 10.1007/BF01317504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01317504</ArticleId><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindarov LM, Chumakov MP, Voroshilova MK, Bojinov S, Vasilenko SM, Iordanov I, Kirov ID, Kamenov E, Leshchinskaya EV, Mitov G. et al.Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol. 1979;23:284&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">231067</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982;71:217&#x2013;227. doi: 10.1007/BF01314873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01314873</ArticleId><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KY, Zhang X, Chung PH, Tsao KC, Lin TY, Su LH, Chiu CH. Enterovirus 71 in Taiwan, 2004-2006: epidemiological and virological features. Scand J Infect Dis. 2008;40:571&#x2013;574. doi: 10.1080/00365540701799359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365540701799359</ArticleId><ArticleId IdType="pubmed">18584550</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol. 1999;73:9969&#x2013;9975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9:78&#x2013;85. doi: 10.3201/eid1301.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuBakar S, Chee HY, Al-Kobaisi MF, Xiaoshan J, Chua KB, Lam SK. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res. 1999;61:1&#x2013;9. doi: 10.1016/S0168-1702(99)00019-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-1702(99)00019-2</ArticleId><ArticleId IdType="pubmed">10426204</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, Huo X, Zhou J, Wu Y, Yan D. et al.The persistent circulation of enterovirus 71 in People&#x2019;s Republic of China: causing emerging nationwide epidemics since 2008. PLoS One. 2011;6:e25662. doi: 10.1371/journal.pone.0025662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L. et al.An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol. 2009;44:262&#x2013;267. doi: 10.1016/j.jcv.2009.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.02.002</ArticleId><ArticleId IdType="pubmed">19269888</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang J, Guo W, Wang H, Zhu S, Wang D, Bai R, Li X, Yan D, Zhu Z. et al.Emergence and transmission pathways of rapidly evolving evolutionary branch C4a strains of human enterovirus 71 in the Central Plain of China. PLoS One. 2011;6:e27895. doi: 10.1371/journal.pone.0027895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027895</ArticleId><ArticleId IdType="pmc">PMC3220707</ArticleId><ArticleId IdType="pubmed">22125635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A. et al.An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94. doi: 10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu RN, Qian Y, Deng J, Xing JF, Zhao LQ, Wang F, Liao B, Ren XX, Li Y, Zhang Q, Li J. Study on the association of hand, foot and mouth disease and enterovirus 71/CA16 among children in Beijing, 2007. Zhonghua Liu Xing Bing Xue Za Zhi. 2007;28:1004&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">18399150</ArticleId></ArticleIdList></Reference><Reference><Citation>le Thoa PK, Chiang PS, Khanh TH, Luo ST, Dan TN, Wang YF, Thuong TC, Chung WY, Hung NT, Wang JR. et al.Genetic and antigenic characterization of enterovirus 71 in Ho Chi Minh city, Vietnam, 2011. PLoS One. 2013;8:e69895. doi: 10.1371/journal.pone.0069895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0069895</ArticleId><ArticleId IdType="pmc">PMC3726754</ArticleId><ArticleId IdType="pubmed">23922846</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas T. Enterovirus 71 causes hand, foot and mouth disease outbreak in Cambodia. Natl Med J India. 2012;25:316.</Citation><ArticleIdList><ArticleId IdType="pubmed">23448647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097&#x2013;1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, Lee CY. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999;354:1682&#x2013;1686. doi: 10.1016/S0140-6736(99)04434-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, Lin KL, Huang YC, Lu CY, Lin TY. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007;356:1226&#x2013;1234. doi: 10.1056/NEJMoa065954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa065954</ArticleId><ArticleId IdType="pubmed">17377160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang LQ, Xu MY, Yin Z. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res. 2013;97:183&#x2013;194. doi: 10.1016/j.antiviral.2012.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.005</ArticleId><ArticleId IdType="pubmed">23261847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo RL, Shih SR. Strategies to develop antivirals against enterovirus 71. Virol J. 2013;10:28. doi: 10.1186/1743-422X-10-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-28</ArticleId><ArticleId IdType="pmc">PMC3614426</ArticleId><ArticleId IdType="pubmed">23339605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012;8:1775&#x2013;1783. doi: 10.4161/hv.21739.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Haywood AM. Virus receptors: binding, adhesion strengthening, and changes in viral structure. J Virol. 1994;68:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236257</ArticleId><ArticleId IdType="pubmed">8254718</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol. 2013;87:611&#x2013;620. doi: 10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Chuang H, Yang KD. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J. 2009;6:141. doi: 10.1186/1743-422X-6-141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-141</ArticleId><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR, Chang CF. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol. 2012;12:162. doi: 10.1186/1471-2180-12-162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-12-162</ArticleId><ArticleId IdType="pmc">PMC3478995</ArticleId><ArticleId IdType="pubmed">22853823</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15:798&#x2013;801. doi: 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794&#x2013;797. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol. 2013;87:3335&#x2013;3347. doi: 10.1128/JVI.02070-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02070-12</ArticleId><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li X. et al.Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem. 2012;287:6406&#x2013;6420. doi: 10.1074/jbc.M111.301622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.301622</ArticleId><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, Hsiao KN, Chitra E, Tsou YL, Chang HW, Sia C. et al.Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One. 2013;8:e57591. doi: 10.1371/journal.pone.0057591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, Shimanuki M, Shitara H, Taya C, Koike S. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A. 2013;110:14753&#x2013;14758. doi: 10.1073/pnas.1217563110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HY, Yang YT, Yu SL, Hsiao KN, Liu CC, Sia C, Chow YH. Caveolar endocytosis is required for human PSGL-1-mediated enterovirus 71 infection. J Virol. 2013;87:9064&#x2013;9076. doi: 10.1128/JVI.00573-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00573-13</ArticleId><ArticleId IdType="pmc">PMC3754029</ArticleId><ArticleId IdType="pubmed">23760234</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Dong W, Quan X, Ma C, Qin C, Zhang L. Transgenic expression of human P-selectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice. Arch Virol. 2012;157:539&#x2013;543. doi: 10.1007/s00705-011-1198-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1198-2</ArticleId><ArticleId IdType="pubmed">22187102</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar HR, Poh CL, Fecondo J, Grollo L. In vitro evaluation of the antiviral activity of heparan sulphate mimetic compounds against enterovirus 71. Virus Res. 2012;169:22&#x2013;29. doi: 10.1016/j.virusres.2012.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008;89:2518&#x2013;2530. doi: 10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu YH, Chan YL, Tsai LW, Li TL, Wu CJ. Prevention of human enterovirus 71 infection by kappa carrageenan. Antiviral Res. 2012;95:128&#x2013;134. doi: 10.1016/j.antiviral.2012.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.05.009</ArticleId><ArticleId IdType="pubmed">22643729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Chan YF, Sim KM, Tan EL, Poh CL. Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1. PLoS One. 2012;7:e34589. doi: 10.1371/journal.pone.0034589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034589</ArticleId><ArticleId IdType="pmc">PMC3341398</ArticleId><ArticleId IdType="pubmed">22563456</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari V, Liu J, Valyi-Nagy T, Shukla D. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J Biol Chem. 2011;286:25406&#x2013;25415. doi: 10.1074/jbc.M110.201103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.201103</ArticleId><ArticleId IdType="pmc">PMC3137111</ArticleId><ArticleId IdType="pubmed">21596749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HL, Wang LC, Chang CH, Yen CC, Cheng WT, Wu SC, Hung CM, Kuo MF, Chen CM. Recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonatal mice from a lethal challenge with enterovirus type 71. Vaccine. 2008;26:891&#x2013;898. doi: 10.1016/j.vaccine.2007.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.12.013</ArticleId><ArticleId IdType="pubmed">18207613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chu C, Chiu CH. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J Infect Dis. 2002;186:1161&#x2013;1164. doi: 10.1086/343809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/343809</ArticleId><ArticleId IdType="pubmed">12355368</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng TY, Chen LC, Shyu HW, Chen SH, Wang JR, Yu CK, Lei HY, Yeh TM. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 2005;67:31&#x2013;37. doi: 10.1016/j.antiviral.2005.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2005.03.005</ArticleId><ArticleId IdType="pubmed">15916817</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog. 2013;9:e1003240. doi: 10.1371/journal.ppat.1003240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MP, Otto MJ, McKinlay MA. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother. 1986;30:110&#x2013;116. doi: 10.1128/AAC.30.1.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.30.1.110</ArticleId><ArticleId IdType="pmc">PMC176446</ArticleId><ArticleId IdType="pubmed">3019232</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay MA, Frank JA Jr, Benziger DP, Steinberg BA. Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice. J Infect Dis. 1986;154:676&#x2013;681. doi: 10.1093/infdis/154.4.676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/154.4.676</ArticleId><ArticleId IdType="pubmed">3745975</ArticleId></ArticleIdList></Reference><Reference><Citation>See DM, Tilles JG. Treatment of coxsackievirus A9 myocarditis in mice with WIN 54954. Antimicrob Agents Chemother. 1992;36:425&#x2013;428. doi: 10.1128/AAC.36.2.425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.36.2.425</ArticleId><ArticleId IdType="pmc">PMC188451</ArticleId><ArticleId IdType="pubmed">1318683</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ, Rossmann MG. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci U S A. 2013;110:5463&#x2013;5467. doi: 10.1073/pnas.1222379110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222379110</ArticleId><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia KS, Li WT, Chang CM, Hsu MC, Chern JH, Leong MK, Tseng SN, Lee CC, Lee YC, Chen SJ. et al.Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem. 2002;45:1644&#x2013;1655. doi: 10.1021/jm010536a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm010536a</ArticleId><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Chen SJ, Hakimelahi GH, Liu HJ, Tseng CT, Shia KS. Selective human enterovirus and rhinovirus inhibitors: an overview of capsid-binding and protease-inhibiting molecules. Med Res Rev. 2004;24:449&#x2013;474. doi: 10.1002/med.10067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.10067</ArticleId><ArticleId IdType="pmc">PMC7168432</ArticleId><ArticleId IdType="pubmed">15170592</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, Lee YC. et al.Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother. 2004;48:3523&#x2013;3529. doi: 10.1128/AAC.48.9.3523-3529.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.9.3523-3529.2004</ArticleId><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Liu SC, Huang PN, Chang HY, Chern JH, Shih SR. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J Biomed Sci. 2008;15:291&#x2013;300. doi: 10.1007/s11373-007-9228-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11373-007-9228-5</ArticleId><ArticleId IdType="pubmed">18196474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chern JH, Shia KS, Hsu TA, Tai CL, Lee CC, Lee YC, Chang CS, Tseng SN, Shih SR. Design, synthesis, and structure-activity relationships of pyrazolo [3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors. Bioorg Med Chem Lett. 2004;14:2519&#x2013;2525. doi: 10.1016/j.bmcl.2004.02.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2004.02.092</ArticleId><ArticleId IdType="pubmed">15109643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CS, Lin YT, Shih SR, Lee CC, Lee YC, Tai CL, Tseng SN, Chern JH. Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives. J Med Chem. 2005;48:3522&#x2013;3535. doi: 10.1021/jm050033v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm050033v</ArticleId><ArticleId IdType="pubmed">15887961</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43:2109&#x2013;2115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y. et al.In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157:669&#x2013;679. doi: 10.1007/s00705-011-1222-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1222-6</ArticleId><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother. 2004;48:1766&#x2013;1772. doi: 10.1128/AAC.48.5.1766-1772.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.5.1766-1772.2004</ArticleId><ArticleId IdType="pmc">PMC400527</ArticleId><ArticleId IdType="pubmed">15105133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman MS, Minor I, Rossmann MG, Diana GD, Andries K. Human rhinovirus 14 complexed with antiviral compound R 61837. J Mol Biol. 1991;217:455&#x2013;463. doi: 10.1016/0022-2836(91)90749-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(91)90749-V</ArticleId><ArticleId IdType="pubmed">1847215</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese D, Conti C, Tomao P, Desideri N, Stein ML, Catone S, Fiore L. Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro. Antiviral Res. 1995;27:123&#x2013;136. doi: 10.1016/0166-3542(95)00088-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(95)00088-4</ArticleId><ArticleId IdType="pubmed">7486950</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti C, Mastromarino P, Sgro R, Desideri N. Anti-picornavirus activity of synthetic flavon-3-yl esters. Antivir Chem Chemother. 1998;9:511&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">9865389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer DJ, Selway JW, Batchelor JF, Tisdale M, Caldwell IC, Young DA. 4&#x2032;,6-Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature. 1981;292:369&#x2013;370. doi: 10.1038/292369a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/292369a0</ArticleId><ArticleId IdType="pmc">PMC7094996</ArticleId><ArticleId IdType="pubmed">6265792</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisdale M, Selway JW. Inhibition of an early stage of rhinovirus replication by dichloroflavan (BW683C) J Gen Virol. 1983;64:795&#x2013;803. doi: 10.1099/0022-1317-64-4-795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-64-4-795</ArticleId><ArticleId IdType="pubmed">6300302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisdale M, Selway JW. Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B. J Antimicrob Chemother. 1984;14(Suppl A):97&#x2013;105. doi: 10.1093/jac/14.suppl_A.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/14.suppl_A.97</ArticleId><ArticleId IdType="pubmed">6092321</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson SR, Sarnow P. Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. Virology. 2003;315:259&#x2013;266. doi: 10.1016/S0042-6822(03)00544-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0042-6822(03)00544-0</ArticleId><ArticleId IdType="pubmed">14592777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Chen TC, Weng KF, Chang SC, Chen LL, Shih SR. Viral and host proteins involved in picornavirus life cycle. J Biomed Sci. 2009;16:103. doi: 10.1186/1423-0127-16-103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-16-103</ArticleId><ArticleId IdType="pmc">PMC2785775</ArticleId><ArticleId IdType="pubmed">19925687</ArticleId></ArticleIdList></Reference><Reference><Citation>Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:125&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4743652</ArticleId><ArticleId IdType="pubmed">22262036</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng JX, Nie XJ, Lei YF, Ma CF, Xu DL, Li B, Xu ZK, Zhang GC. The highly conserved 5&#x2032; untranslated region as an effective target towards the inhibition of enterovirus 71 replication by unmodified and appropriate 2&#x2032;- modified siRNAs. J Biomed Sci. 2012;19:73. doi: 10.1186/1423-0127-19-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-19-73</ArticleId><ArticleId IdType="pmc">PMC3438048</ArticleId><ArticleId IdType="pubmed">22889374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Yang F, Zhao R, Zhao L, Guo D, Jin Q. Identification of small interfering RNAs which inhibit the replication of several enterovirus 71 strains in China. J Virol Methods. 2009;159:233&#x2013;238. doi: 10.1016/j.jviromet.2009.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2009.04.002</ArticleId><ArticleId IdType="pubmed">19490979</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim AC, Luhur A, Tan TM, Chow VT, Poh CL. RNA interference against enterovirus 71 infection. Virology. 2005;341:72&#x2013;79. doi: 10.1016/j.virol.2005.06.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.06.047</ArticleId><ArticleId IdType="pubmed">16083932</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EL, Tan TM, Tak Kwong Chow V, Poh CL. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol Ther. 2007;15:1931&#x2013;1938. doi: 10.1038/sj.mt.6300287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mt.6300287</ArticleId><ArticleId IdType="pubmed">17712333</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EL, Tan TM, Chow VT, Poh CL. Enhanced potency and efficacy of 29-mer shRNAs in inhibition of enterovirus 71. Antiviral Res. 2007;74:9&#x2013;15. doi: 10.1016/j.antiviral.2007.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2007.01.004</ArticleId><ArticleId IdType="pubmed">17316836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu WW, Hsu YY, Yang JY, Kung SH. Selective inhibition of enterovirus 71 replication by short hairpin RNAs. Biochem Biophys Res Commun. 2004;325:494&#x2013;499. doi: 10.1016/j.bbrc.2004.10.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.10.062</ArticleId><ArticleId IdType="pubmed">15530419</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JK, Rijnbrand R, Stein DA, Ma Y, Yang Y, Iversen PL, Andino R. A morpholino oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple species of picornavirus. Antimicrob Agents Chemother. 2008;52:1970&#x2013;1981. doi: 10.1128/AAC.00011-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00011-08</ArticleId><ArticleId IdType="pmc">PMC2415775</ArticleId><ArticleId IdType="pubmed">18347107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Stein DA, Lim T, Qiu D, Coughlin S, Liu Z, Wang Y, Blouch R, Moulton HM, Iversen PL, Yang D. Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J Virol. 2006;80:11510&#x2013;11519. doi: 10.1128/JVI.00900-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00900-06</ArticleId><ArticleId IdType="pmc">PMC1642606</ArticleId><ArticleId IdType="pubmed">16987987</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Du J, Wu Z, Jin Q. Quinacrine impairs enterovirus 71 RNA replication by preventing binding of polypyrimidine-tract binding protein with internal ribosome entry sites. PLoS One. 2013;8:e52954. doi: 10.1371/journal.pone.0052954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052954</ArticleId><ArticleId IdType="pmc">PMC3536785</ArticleId><ArticleId IdType="pubmed">23301007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai FJ, Lin CW, Lai CC, Lan YC, Lai CH, Hung CH, Hsueh KC, Lin TH, Chang HC, Wan L. et al.Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins. Food Chem. 2011;128:312&#x2013;322. doi: 10.1016/j.foodchem.2011.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2011.03.022</ArticleId><ArticleId IdType="pubmed">25212137</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YJ, Lai CC, Lai CH, Sue SC, Lin CW, Hung CH, Lin TH, Hsu WY, Huang SM, Hung YL. et al.Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide. Eur J Med Chem. 2013;62:206&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">23353754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Zeng SJ, Hsu JT, Horng JT, Yang HM, Shih SR, Chu YT, Wu TY. Amantadine as a regulator of internal ribosome entry site. Acta Pharmacol Sin. 2008;29:1327&#x2013;1333. doi: 10.1111/j.1745-7254.2008.00876.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7254.2008.00876.x</ArticleId><ArticleId IdType="pubmed">18954527</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies WL, Grunert RR, Hoffmann CE. Influenza virus growth and antibody response in amantadine-treated mice. J Immunol. 1965;95:1090&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">5850540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann CE, Neumayer EM, Haff RF, Goldsby RA. Mode of action of the antiviral activity of amantadine in tissue culture. J Bacteriol. 1965;90:623&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC315701</ArticleId><ArticleId IdType="pubmed">16562058</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Xi X, Lei X, Zhang X, Cui S, Wang J, Jin Q, Zhao Z. Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses. PLoS Pathog. 2013;9:e1003231. doi: 10.1371/journal.ppat.1003231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003231</ArticleId><ArticleId IdType="pmc">PMC3605153</ArticleId><ArticleId IdType="pubmed">23555247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Xiao X, Xue Q, Jin Q, He B, Wang J. Cleavage of interferon regulatory factor 7 by enterovirus 71 3C suppresses cellular responses. J Virol. 2013;87:1690&#x2013;1698. doi: 10.1128/JVI.01855-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01855-12</ArticleId><ArticleId IdType="pmc">PMC3554134</ArticleId><ArticleId IdType="pubmed">23175366</ArticleId></ArticleIdList></Reference><Reference><Citation>Falah N, Montserret R, Lelogeais V, Schuffenecker I, Lina B, Cortay JC, Violot S. Blocking human enterovirus 71 replication by targeting viral 2A protease. J Antimicrob Chemother. 2012;67:2865&#x2013;2869. doi: 10.1093/jac/dks304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks304</ArticleId><ArticleId IdType="pubmed">22865380</ArticleId></ArticleIdList></Reference><Reference><Citation>Witherell G. AG-7088 Pfizer. Curr Opin Investig Drugs. 2000;1:297&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">11249711</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, Matthews DA, Patick AK. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother. 2005;49:619&#x2013;626. doi: 10.1128/AAC.49.2.619-626.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.2.619-626.2005</ArticleId><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2007;51:4366&#x2013;4373. doi: 10.1128/AAC.00905-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00905-07</ArticleId><ArticleId IdType="pmc">PMC2167992</ArticleId><ArticleId IdType="pubmed">17908951</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71:391&#x2013;396. doi: 10.1016/j.antiviral.2006.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2006.03.011</ArticleId><ArticleId IdType="pmc">PMC7132408</ArticleId><ArticleId IdType="pubmed">16675037</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ. et al.In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999;43:2444&#x2013;2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2005;49:2267&#x2013;2275. doi: 10.1128/AAC.49.6.2267-2275.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.6.2267-2275.2005</ArticleId><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XN, Song ZG, Jiang T, Shi BS, Hu YW, Yuan ZH. Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection. World J Gastroenterol. 2010;16:201&#x2013;209. doi: 10.3748/wjg.v16.i2.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i2.201</ArticleId><ArticleId IdType="pmc">PMC2806558</ArticleId><ArticleId IdType="pubmed">20066739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, Hsu JT. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis. 2011;203:1784&#x2013;1790. doi: 10.1093/infdis/jir174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir174</ArticleId><ArticleId IdType="pubmed">21536800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Qi J, Chen Z, Xu X, Gao F, Lin D, Qian W, Liu H, Jiang H, Yan J, Gao GF. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011;85:10319&#x2013;10331. doi: 10.1128/JVI.00787-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Song Z, Qin B, Chen L, Hu Y, Yuan Z. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res. 2013;97:264&#x2013;269. doi: 10.1016/j.antiviral.2012.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.029</ArticleId><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Fan T, Yao X, Wu Z, Guo L, Lei X, Wang M, Jin Q, Cui S. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol. 2011;85:10021&#x2013;10030. doi: 10.1128/JVI.05107-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05107-11</ArticleId><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Cai Q, Chen C, Li N, Peng X, Cai Y, Yin K, Chen X, Wang X, Zhang R. et al.Structures of enterovirus 71 3C proteinase (strain E2004104-TW-CDC) and its complex with rupintrivir. Acta Crystallogr D Biol Crystallogr. 2013;69:866&#x2013;871. doi: 10.1107/S0907444913002862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444913002862</ArticleId><ArticleId IdType="pubmed">23633597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CJ, Shie JJ, Fang JM, Yen GR, Hsu JT, Liu HG, Tseng SN, Chang SC, Lee CY, Shih SR, Liang PH. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem. 2008;16:7388&#x2013;7398. doi: 10.1016/j.bmc.2008.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2008.06.015</ArticleId><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YJ, Chang YC, Hsiao NW, Hsieh JL, Wang CY, Kung SH, Tsai FJ, Lan YC, Lin CW. Fisetin and rutin as 3C protease inhibitors of enterovirus A71. J Virol Methods. 2012;182:93&#x2013;98. doi: 10.1016/j.jviromet.2012.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.03.020</ArticleId><ArticleId IdType="pubmed">22465253</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust RC, Landmann L, Gosert R, Tang BL, Hong W, Hauri HP, Egger D, Bienz K. Cellular COPII proteins are involved in production of the vesicles that form the poliovirus replication complex. J Virol. 2001;75:9808&#x2013;9818. doi: 10.1128/JVI.75.20.9808-9818.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.20.9808-9818.2001</ArticleId><ArticleId IdType="pmc">PMC114553</ArticleId><ArticleId IdType="pubmed">11559814</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger D, Teterina N, Ehrenfeld E, Bienz K. Formation of the poliovirus replication complex requires coupled viral translation, vesicle production, and viral RNA synthesis. J Virol. 2000;74:6570&#x2013;6580. doi: 10.1128/JVI.74.14.6570-6580.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.14.6570-6580.2000</ArticleId><ArticleId IdType="pmc">PMC112167</ArticleId><ArticleId IdType="pubmed">10864671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson WT, Giddings TH Jr, Taylor MP, Mulinyawe S, Rabinovitch M, Kopito RR, Kirkegaard K. Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biol. 2005;3:e156. doi: 10.1371/journal.pbio.0030156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0030156</ArticleId><ArticleId IdType="pmc">PMC1084330</ArticleId><ArticleId IdType="pubmed">15884975</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SC, Chang CL, Wang PS, Tsai Y, Liu HS. Enterovirus 71-induced autophagy detected in vitro and in vivo promotes viral replication. J Med Virol. 2009;81:1241&#x2013;1252. doi: 10.1002/jmv.21502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21502</ArticleId><ArticleId IdType="pmc">PMC7166624</ArticleId><ArticleId IdType="pubmed">19475621</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol. 2009;90:1869&#x2013;1879. doi: 10.1099/vir.0.012096-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.012096-0</ArticleId><ArticleId IdType="pubmed">19439558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shima Y, Okamoto T, Aoyama T, Yasura K, Ishibe T, Nishijo K, Shibata KR, Kohno Y, Fukiage K, Otsuka S. et al.In vitro transformation of mesenchymal stem cells by oncogenic H-rasVal12. Biochem Biophys Res Commun. 2007;353:60&#x2013;66. doi: 10.1016/j.bbrc.2006.11.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.11.137</ArticleId><ArticleId IdType="pubmed">17173860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, Mazure NM. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 2009;29:2570&#x2013;2581. doi: 10.1128/MCB.00166-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00166-09</ArticleId><ArticleId IdType="pmc">PMC2682037</ArticleId><ArticleId IdType="pubmed">19273585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou YL, Lin YW, Chang HW, Lin HY, Shao HY, Yu SL, Liu CC, Chitra E, Sia C, Chow YH. Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy. PLoS One. 2013;8:e77133. doi: 10.1371/journal.pone.0077133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077133</ArticleId><ArticleId IdType="pmc">PMC3788750</ArticleId><ArticleId IdType="pubmed">24098578</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferle S, Schopf J, Kogl M, Friedel CC, Muller MA, Carbajo-Lozoya J, Stellberger T, von Dall&#x2019;Armi E, Herzog P, Kallies S. et al.The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011;7:e1002331. doi: 10.1371/journal.ppat.1002331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002331</ArticleId><ArticleId IdType="pmc">PMC3203193</ArticleId><ArticleId IdType="pubmed">22046132</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcellin P, Horsmans Y, Nevens F, Grange JD, Bronowicki JP, Vetter D, Purdy S, Garg V, Bengtsson L, McNair L, Alam J. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. J Hepatol. 2007;47:476&#x2013;483. doi: 10.1016/j.jhep.2007.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2007.03.028</ArticleId><ArticleId IdType="pubmed">17629590</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Gil L, Bano-Polo M, Redondo N, Sanchez-Martinez S, Nieva JL, Carrasco L, Mingarro I. Membrane integration of poliovirus 2B viroporin. J Virol. 2011;85:11315&#x2013;11324. doi: 10.1128/JVI.05421-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05421-11</ArticleId><ArticleId IdType="pmc">PMC3194936</ArticleId><ArticleId IdType="pubmed">21835803</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie S, Wang K, Yu W, Lu W, Xu K, Wang J, Ye B, Schwarz W, Jin Q, Sun B. DIDS blocks a chloride-dependent current that is mediated by the 2B protein of enterovirus 71. Cell Res. 2011;21:1271&#x2013;1275. doi: 10.1038/cr.2011.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2011.112</ArticleId><ArticleId IdType="pmc">PMC3193483</ArticleId><ArticleId IdType="pubmed">21747413</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams P, Kandiah E, Effantin G, Steven AC, Ehrenfeld E. Poliovirus 2C protein forms homo-oligomeric structures required for ATPase activity. J Biol Chem. 2009;284:22012&#x2013;22021. doi: 10.1074/jbc.M109.031807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.031807</ArticleId><ArticleId IdType="pmc">PMC2755925</ArticleId><ArticleId IdType="pubmed">19520852</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Agoh M, Agoh Y, Yoshida H, Yoshii K, Yoneyama T, Hagiwara A, Miyamura T. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol. 2000;74:4146&#x2013;4154. doi: 10.1128/JVI.74.9.4146-4154.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.9.4146-4154.2000</ArticleId><ArticleId IdType="pmc">PMC111929</ArticleId><ArticleId IdType="pubmed">10756027</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E. et al.Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009;53:1850&#x2013;1857. doi: 10.1128/AAC.00934-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00934-08</ArticleId><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliguiri LA, Tamm I. Distribution and translation of poliovirus RNA in guanidine-treated cells. Virology. 1968;36:223&#x2013;231. doi: 10.1016/0042-6822(68)90139-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(68)90139-6</ArticleId><ArticleId IdType="pubmed">4300879</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliguiri LA, Tamm I. Action of guanidine on the replication of poliovirus RNA. Virology. 1968;35:408&#x2013;417. doi: 10.1016/0042-6822(68)90219-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(68)90219-5</ArticleId><ArticleId IdType="pubmed">4298649</ArticleId></ArticleIdList></Reference><Reference><Citation>Loddo B, Ferrari W, Brotzu G, Spanedda A. In vitro inhibition of infectivity of polio viruses by guanidine. Nature. 1962;193:97&#x2013;98. doi: 10.1038/193097a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/193097a0</ArticleId><ArticleId IdType="pubmed">14466152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rightsel WA, Dice JR, Mc AR, Timm EA, Mc LI Jr, Dixon GJ, Schabel FM Jr. Antiviral effect of guanidine. Science. 1961;134:558&#x2013;559. doi: 10.1126/science.134.3478.558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.134.3478.558</ArticleId><ArticleId IdType="pubmed">13741634</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann EC Jr, Herrmann JA, Delong DC. Prevention of death in mice infected with coxsackievirus A16 using guanidine HCl mixed with substituted benzimidazoles. Antiviral Res. 1982;2:339&#x2013;346. doi: 10.1016/0166-3542(82)90003-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(82)90003-1</ArticleId><ArticleId IdType="pubmed">6299189</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders K, King AM, McCahon D, Newman JW, Slade WR, Forss S. Recombination and oligonucleotide analysis of guanidine-resistant foot-and-mouth disease virus mutants. J Virol. 1985;56:921&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC252665</ArticleId><ArticleId IdType="pubmed">2999445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S, Bek EJ, McMinn PC. Selection and characterisation of guanidine-resistant mutants of human enterovirus 71. Virus Res. 2012;169:72&#x2013;79. doi: 10.1016/j.virusres.2012.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2012.07.005</ArticleId><ArticleId IdType="pubmed">22814431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienz K, Egger D, Troxler M, Pasamontes L. Structural organization of poliovirus RNA replication is mediated by viral proteins of the P2 genomic region. J Virol. 1990;64:1156&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249229</ArticleId><ArticleId IdType="pubmed">2154600</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MP, Burgon TB, Kirkegaard K, Jackson WT. Role of microtubules in extracellular release of poliovirus. J Virol. 2009;83:6599&#x2013;6609. doi: 10.1128/JVI.01819-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01819-08</ArticleId><ArticleId IdType="pmc">PMC2698579</ArticleId><ArticleId IdType="pubmed">19369338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels E, Duijsings D, Notebaart RA, Melchers WJ, van Kuppeveld FJ. A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-golgi transport. J Virol. 2005;79:5163&#x2013;5173. doi: 10.1128/JVI.79.8.5163-5173.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.8.5163-5173.2005</ArticleId><ArticleId IdType="pmc">PMC1069528</ArticleId><ArticleId IdType="pubmed">15795300</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev. 2008;28:823&#x2013;884. doi: 10.1002/med.20125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20125</ArticleId><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Takebe Y, Wakita T, Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J Gen Virol. 2010;91:2734&#x2013;2744. doi: 10.1099/vir.0.023374-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.023374-0</ArticleId><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak HB, Arnold JJ, Wiegand PN, Hargittai MR, Cameron CE. Picornavirus genome replication: assembly and organization of the VPg uridylylation ribonucleoprotein (initiation) complex. J Biol Chem. 2007;282:16202&#x2013;16213. doi: 10.1074/jbc.M610608200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M610608200</ArticleId><ArticleId IdType="pmc">PMC2116992</ArticleId><ArticleId IdType="pubmed">17392285</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul AV, Rieder E, Kim DW, van Boom JH, Wimmer E. Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. J Virol. 2000;74:10359&#x2013;10370. doi: 10.1128/JVI.74.22.10359-10370.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.22.10359-10370.2000</ArticleId><ArticleId IdType="pmc">PMC110910</ArticleId><ArticleId IdType="pubmed">11044080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wang Y, Shan C, Chen C, Xu P, Song M, Zhou H, Yang C, Xu W, Shi PY. et al.Enterovirus-71 VPg uridylylation uses a two-molecular mechanism of 3Dpol. J Virol. 2012;86:13662&#x2013;13671. doi: 10.1128/JVI.01712-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01712-12</ArticleId><ArticleId IdType="pmc">PMC3503026</ArticleId><ArticleId IdType="pubmed">23055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, Harki DA, Galarraga JE, Bollinger JM Jr, Peterson BR, Loakes D. et al.Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob Agents Chemother. 2008;52:971&#x2013;979. doi: 10.1128/AAC.01056-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01056-07</ArticleId><ArticleId IdType="pmc">PMC2258490</ArticleId><ArticleId IdType="pubmed">18180344</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZH, Li CM, Ling P, Shen FH, Chen SH, Liu CC, Yu CK. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008;197:854&#x2013;857. doi: 10.1086/527326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/527326</ArticleId><ArticleId IdType="pmc">PMC7109938</ArticleId><ArticleId IdType="pubmed">18279075</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Chang HY, Lin PF, Chern JH, Hsu JT, Chang CY, Shih SR. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009;53:2740&#x2013;2747. doi: 10.1128/AAC.00101-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00101-09</ArticleId><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut HJ, Leyssen P, Puerstinger G, Muigg A, Neyts J, De Palma AM. Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res. 2011;90:213&#x2013;217. doi: 10.1016/j.antiviral.2011.03.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.03.187</ArticleId><ArticleId IdType="pubmed">21466823</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>